Based on the cross-layer design, the power-optimization problem of Macro-Femto Heterogeneous Networks （HetNets） has been formulated. The constraints of power and re-source block allocation in the physical layer, del...Based on the cross-layer design, the power-optimization problem of Macro-Femto Heterogeneous Networks （HetNets） has been formulated. The constraints of power and re-source block allocation in the physical layer, delay and target data rate in the medium ac-cess control layer, urgent queue length in the network layer, and packet error rate in the transport layer, have been considered. The original problem is non-deterministic polyno-mial time hard, which cannot be solved practi-cally. After the restrictions of upper layers are translated into constraints with physical layer parameters, and the integer restrictions are relaxed, the original problem can be decom- posed into convex optimization subproblems. The optimal solutions of resource block allo-cation and power allocation can be obtained by using the Lagrangian optimization. Simula-tion results show that the proposed scheme is better than both the round robin algorithm and the max-rain one in terms of energy efficiency, throughput and service fairness. The round robin algorithm and the max-min one only focus on the user fairness rather than quality of service fairness. Compared to the round robin scheme （the max-min one）, the proposed scheme improves the energy efficiency 58.85% （62.41%）, the throughput 19.09% （25.25%）, the service fairness 57.69% （35.48%）.展开更多
Objective: To investigate the clinical efficacy and safety of the Ganning formula (肝宁方) for the treatment of liver fibrosis in patients with chronic hepatitis B. Methods: In a multicenter, randomized, controlled cl...Objective: To investigate the clinical efficacy and safety of the Ganning formula (肝宁方) for the treatment of liver fibrosis in patients with chronic hepatitis B. Methods: In a multicenter, randomized, controlled clinical trial, 150 patients with liver fibrosis secondary to hepatitis B virus (HBV) infection were randomly assigned in equal numbers to receive either the Ganning formula (a Chinese herbal decoction; active treatment group) or oral entecavir (control group) for two 3-month courses. Patients were monitored for any treatment-induced changes in liver function test parameters (ALT, AST, and GGT), liver fibrosis markers (LN, HA, IV-C, and PCIII), HBV DNA level, hepatosplenic imaging, quality of life scores, or psychological and social functioning scores. Patients were also observed for any adverse effects. Results: After treatment, patients in both groups experienced significant improvements in liver function, HBV DNA load, hepatosplenic B-mode ultrasonography, quality of life, and psychological and social functioning (P<0.05 or P<0.01). Patients receiving the Ganning formula achieved greater improvements in HA, IV-C, quality of life, and psychological and social functioning compared with those on entecavir (P<0.05 or P<0.01). There were no abnormal changes in blood tests, urine, feces, renal function, or electrocardiogram. Additionally, no adverse effects were observed in any patients in either group. Conclusions: The Ganning formula appears to have the potential to inhibit liver fibrosis and therefore improve liver function by inhibiting HBV replication in patients with chronic hepatitis B. Additionally, this formula is helpful in improving quality of life and psychological and social functioning.展开更多
基金supported in part by the project of National Natural Science Foundation of China under Grant No. 61071075National Science and Technology Major Project of China under Grant No. 2010ZX03003-001-02+1 种基金National Science and Technology Major Project of China under Grant No. 2011ZX03004003the Chinese Ministry of Education in the project of the Fundamental Research Funds for the Central Universities under Grant No.2011YJS216
文摘Based on the cross-layer design, the power-optimization problem of Macro-Femto Heterogeneous Networks （HetNets） has been formulated. The constraints of power and re-source block allocation in the physical layer, delay and target data rate in the medium ac-cess control layer, urgent queue length in the network layer, and packet error rate in the transport layer, have been considered. The original problem is non-deterministic polyno-mial time hard, which cannot be solved practi-cally. After the restrictions of upper layers are translated into constraints with physical layer parameters, and the integer restrictions are relaxed, the original problem can be decom- posed into convex optimization subproblems. The optimal solutions of resource block allo-cation and power allocation can be obtained by using the Lagrangian optimization. Simula-tion results show that the proposed scheme is better than both the round robin algorithm and the max-rain one in terms of energy efficiency, throughput and service fairness. The round robin algorithm and the max-min one only focus on the user fairness rather than quality of service fairness. Compared to the round robin scheme （the max-min one）, the proposed scheme improves the energy efficiency 58.85% （62.41%）, the throughput 19.09% （25.25%）, the service fairness 57.69% （35.48%）.
基金supported by the Guangxi Medicine Research Grant Program (No.2010095)the Guangxi Science and Technology Research Grant Program (No.2010GXNSFA013217)the Guangxi Natural Science Foundation (No. 0832174)
文摘Objective: To investigate the clinical efficacy and safety of the Ganning formula (肝宁方) for the treatment of liver fibrosis in patients with chronic hepatitis B. Methods: In a multicenter, randomized, controlled clinical trial, 150 patients with liver fibrosis secondary to hepatitis B virus (HBV) infection were randomly assigned in equal numbers to receive either the Ganning formula (a Chinese herbal decoction; active treatment group) or oral entecavir (control group) for two 3-month courses. Patients were monitored for any treatment-induced changes in liver function test parameters (ALT, AST, and GGT), liver fibrosis markers (LN, HA, IV-C, and PCIII), HBV DNA level, hepatosplenic imaging, quality of life scores, or psychological and social functioning scores. Patients were also observed for any adverse effects. Results: After treatment, patients in both groups experienced significant improvements in liver function, HBV DNA load, hepatosplenic B-mode ultrasonography, quality of life, and psychological and social functioning (P<0.05 or P<0.01). Patients receiving the Ganning formula achieved greater improvements in HA, IV-C, quality of life, and psychological and social functioning compared with those on entecavir (P<0.05 or P<0.01). There were no abnormal changes in blood tests, urine, feces, renal function, or electrocardiogram. Additionally, no adverse effects were observed in any patients in either group. Conclusions: The Ganning formula appears to have the potential to inhibit liver fibrosis and therefore improve liver function by inhibiting HBV replication in patients with chronic hepatitis B. Additionally, this formula is helpful in improving quality of life and psychological and social functioning.
